Edgewise Therapeutics (EWTX) Earnings Analysis

Edgewise Therapeutics (EWTX) next reports earnings on 2026-08-06, consensus EPS -0.48 USD. Last quarter (2026-05-07) it beat with EPS -0.46 USD vs -0.5 USD est (+8%). It has beaten estimates in 3/5 recent quarters (60%). Trailing P/E -23.09.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does EWTX next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.48 USD
Revenue estimaten/a

EWTX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.46 USD-0.5 USD+8%Beat
2026-02-26-0.47 USD-0.43 USD-9.3%Miss
2025-11-06-0.39 USD-0.4 USD+2.5%Beat
2025-05-08-0.43 USD-0.45 USD+4.4%Beat
2025-03-03-0.42 USD-0.39 USD-7.7%Miss

Beat rate: 3/5 (60%) over reported quarters with consensus data.

EWTX valuation and analyst view

Trailing P/E-23.09
Trailing EPS-1.64316 USD
Price / book8.32
Dividend yield0.00%
Market cap4.17B
Analyst consensusBuy (9 buy / 2 hold / 0 sell)
Avg price target51.18 USD

Related research pages

Frequently asked questions

When is Edgewise Therapeutics (EWTX)'s next earnings date?

Edgewise Therapeutics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.48 USD.

Did EWTX beat earnings last quarter?

In its 2026-05-07 report, EWTX posted EPS of -0.46 USD versus a -0.5 USD estimate — a beat of 8%.

What is EWTX's earnings track record?

Over the last 5 reported quarters with consensus data, EWTX beat estimates 3 times (60%).

What is EWTX's current P/E ratio and EPS?

EWTX trades at a trailing P/E of -23.09 on trailing EPS of -1.6431610123496232 USD.

What do analysts rate EWTX?

Analyst consensus is "Buy" across 11 ratings (0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 51.18 USD.